Market Place
Sourcing Support
GNMART Inc Issues Voluntary Nationwide Recall of Force Forever
16 Dec 2024 //
FDA
J&J Files For FDA Approval Of DARZALEX FASPRO Regimen
30 Sep 2024 //
PR NEWSWIRE
Antengene To Commercialise XPOVIO In Thailand For Myeloma
23 Sep 2024 //
BIOSPECTRUM ASIA
123Herbals Issues Voluntary Nationwide Recall of Vail-Bon
20 Sep 2024 //
FDA
Prophylactic Dexamethasone Reduces Reactions In EGFR-Mutated NSCLC
10 Sep 2024 //
GLOBENEWSWIRE
Dexamethasone Reduces RYBREVANT® Infusion Reactions
10 Sep 2024 //
PR NEWSWIRE
DARZALEX FASPRO-Based Quadruplet Regimen Approved For Multiple Myeloma
30 Jul 2024 //
PR NEWSWIRE
Legend Biotech Reports Positive OS Results From CARTITUDE-4 Trial
02 Jul 2024 //
GLOBENEWSWIRE
Starton Therapeutics 100% Partial Response in Multiple Myeloma STAR-LLD Phase 1b
21 Jun 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of June 5, 2024
05 Jun 2024 //
FDA
Zydus receives final approval from USFDA for Dexamethasone Tablets
13 May 2024 //
INDINPHARMAPOST
ProMed Pharma Acquires SpineThera Manufacturing Capabilities
03 Apr 2024 //
BUSINESSWIRE
AffaMed Therapeutics Announces NDA Acceptance by HSA for DEXTENZA
19 Feb 2024 //
PR NEWSWIRE
Zydus Pharma`s Generic Dexamethasone Receives Approval in the U.S.
07 Feb 2024 //
FDA
Zydus Pharma`s Generic Dexamethasone Receives Approval in the U.S.
07 Feb 2024 //
FDA
GSK details combo data that could bring Blenrep back to life
06 Feb 2024 //
FIERCE PHARMA
GSK`s blood cancer drug meets primary goal in late-stage trial
28 Nov 2023 //
REUTERS
Apotex`s Generic Dexamethasone Receives Approval in the U.S.
23 Aug 2023 //
FDA
Akorn`s Generic Ciprofloxacin, Dexamethasone Receives Approval in the U.S.
09 Jun 2023 //
FDA
Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS
31 May 2023 //
PR NEWSWIRE
AffaMed Announces Completion of Enrollment in Study Evaluating Efficacy of DEXTENZA
31 May 2023 //
PR NEWSWIRE
Novitium`s Generic Dexamethasone Receives Receives Approval in the U.S.
09 May 2023 //
FDA
AffaMed Therapeutics Announces Approval to Initiate a Ph3 TriaL
17 Apr 2023 //
PR NEWSWIRE
Karyopharm and Menarini Group Receive Full Marketing Authorization for NEXPOVIO
21 Feb 2023 //
PR NEWSWIRE
Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE
23 Jan 2023 //
BUSINESSWIRE
Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M
15 Dec 2022 //
FIERCEPHARMA
Janssen Presents Efficacy Analyses from MAIA Study Showing Results of DARZALEX
12 Dec 2022 //
PRNEWSWIRE
SpineThera Announces Results for SX600 from SALIENT Phase 2 Sciatica Pain Trial
07 Dec 2022 //
BUSINESSWIRE
Sun`s Generic Ciprofloxacin,Dexamethasone Receives Approval in the U.S.
30 Aug 2022 //
FDA
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
29 Aug 2022 //
CLINICALTRIALSARENA
Martin Landray says they can be done for a tiny fraction of the cost
18 Aug 2022 //
ENDPTS
ANI Pharma Announces FDA Approval and Launch of Dexamethasone Tablets USP
16 Aug 2022 //
BUSINESSWIRE
Santen launches Ducressa for post-cataract surgery
15 Aug 2022 //
PHARMATIMES
Allena Pharmaceuticals Warns of Imminent Funding Need
11 Aug 2022 //
FIRSTWORDPHARMA
NICE Recommendation Expands Patient Eligibility for AbbVie’s Ozurdex
11 Aug 2022 //
NEWSCISION
Trio of therapies reduces risk of death in patients with severe COVID-19
11 Aug 2022 //
EUROPEAN PHARMACEUTICAL REVIEW
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
10 Aug 2022 //
PHARMA TIMES
SMC accepts first licensed treatment for newly diagnosed AL amyloidosis
09 Aug 2022 //
PHARMAFILE
Novitium Pharma Generic Dexamethasone Receives Approval in the U.S.
08 Aug 2022 //
FDA
Enforcement Report - Week of June 15, 2022
14 Jun 2022 //
FDA
Sanofi reports positive Phase III multiple myeloma trial results
16 May 2022 //
CLINICALTRIALSARENA
Optifye and DelSiTech partner on controlled-release eye drops
30 Mar 2022 //
FIERCEPHARMA
Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Tobradex® Ophthalmic Suspension
21 Mar 2022 //
PRESS RELEASE
TGA Approves Antengene`s XPOVIO for r/r and TCR Multiple Myeloma
09 Mar 2022 //
PRNEWSWIRE
Teva launches Revlimid generic, the first to do so in U.S.
08 Mar 2022 //
FIERCEPHARMA
Padagis` Generic Tobramycin and Dexamethasone Receives Approval in the U.S.
11 Feb 2022 //
FDA
Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
07 Feb 2022 //
GLOBENEWSWIRE
AffaMed Doses First Patient in Trial Evaluating DEXTENZA in Cataract Surgery
18 Jan 2022 //
BUSINESSWIRE
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
12 Jan 2022 //
PRNEWSWIRE
Hameln has received certificate “Union Format for Registration of Manufacturer
03 Jan 2022 //
PRESS RELEASE
NICE recommends combination treatment for patients with multiple myeloma
24 Dec 2021 //
PHARMAFILE
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
20 Dec 2021 //
BUSINESSWIRE
New Clinical and Real-World Data Support Use of DARZALEX in MM
11 Dec 2021 //
BUSINESSWIRE
Sanofi`s Sarclisa, J&J`s Darzalex clash in 4-drug myeloma trials
11 Dec 2021 //
FIERCEPHARMA
FDA Grants Approval to Janssen`s DARZALEX FASPRO + Carfilzomib & Dexamethasone
01 Dec 2021 //
PRNEWSWIRE
NTC, Aspen announce +ve SAHPRA result for levofloxacin+dexamethasone eye drops
24 Nov 2021 //
PRNEWSWIRE
J&J thinks it could have 14 new blockbusters by 2025
19 Nov 2021 //
REUTERS
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
27 Oct 2021 //
BUSINESSWIRE
